Literature DB >> 1835900

Inhibition of protein isoprenylation and p21ras membrane association by dehydroepiandrosterone in human colonic adenocarcinoma cells in vitro.

S Schulz1, J W Nyce.   

Abstract

Treatment of mice and rats with the adrenal steroid, dehydroepiandrosterone (DHEA), protects against spontaneous and chemically induced tumors. The mechanism of the chemopreventive action of DHEA, however, remains uncertain. DHEA has been reported to inhibit cholesterol biosynthesis. Mevalonic acid constitutes the basic precursor not only for cholesterol but also for a variety of nonsterol isoprenoids involved in cell growth. Certain of these nonsterol isoprenoids are utilized for posttranslational modification of proteins including p21ras. We therefore investigated the effects of DHEA upon protein isoprenylation. Twenty-four-h exposure of HT-29 SF human colonic adenocarcinoma cells to 50 microM DHEA was associated with significant incorporation of products of [3H]mevalonate metabolism into several size classes of cellular proteins. The pattern of incorporation was similar to that obtained after treatment with 25 microM lovastatin, a specific 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor. Very little incorporation of label from [3H]mevalonate was observed in untreated cells. This suggests that [3H]mevalonate gains entrance to isoprenylation sites after treatment with DHEA or lovastatin because of depletion of endogenous mevalonate and subsequent inhibition of protein isoprenylation. Isoprenylation plays a critical role in promoting the association of p21ras with the cell membrane. Posttranslational processing and membrane association of p21ras were both found to be inhibited by DHEA. Thus, it is possible that the inhibition of isoprenylation of p21ras and other cellular proteins by DHEA may contribute to its anti-cancer effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1835900

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

2.  Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone.

Authors:  Noriyuki Homma; Tetsutaro Nagaoka; Vijaya Karoor; Masatoshi Imamura; Laimute Taraseviciene-Stewart; Lori A Walker; Karen A Fagan; Ivan F McMurtry; Masahiko Oka
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-05-09       Impact factor: 5.464

3.  Control of RAS mRNA level by the mevalonate pathway.

Authors:  D Dimster-Denk; W R Schafer; J Rine
Journal:  Mol Biol Cell       Date:  1995-01       Impact factor: 4.138

4.  Autoinflammatory Reaction in Dogs Treated for Cancer via G6PD Inhibition.

Authors:  Jonathan W Nyce
Journal:  Case Rep Vet Med       Date:  2017-08-08

Review 5.  Detection of a novel, primate-specific 'kill switch' tumor suppression mechanism that may fundamentally control cancer risk in humans: an unexpected twist in the basic biology of TP53.

Authors:  Jonathan W Nyce
Journal:  Endocr Relat Cancer       Date:  2018-06-25       Impact factor: 5.678

Review 6.  Gender, sex hormones and pulmonary hypertension.

Authors:  Eric D Austin; Tim Lahm; James West; Stevan P Tofovic; Anne Katrine Johansen; Margaret R Maclean; Abdallah Alzoubi; Masahiko Oka
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

7.  Structurally novel steroidal spirooxindole by241 potently inhibits tumor growth mainly through ROS-mediated mechanisms.

Authors:  Xiao-Jing Shi; Bin Yu; Jun-Wei Wang; Ping-Ping Qi; Kai Tang; Xin Huang; Hong-Min Liu
Journal:  Sci Rep       Date:  2016-08-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.